Lyrica met goal in study of central neuropathic pain after spinal cord injury
This article was originally published in Scrip
Executive Summary
Pfizer has reported that its GABA analogue, Lyrica (pregabalin), met its primary endpoint of positive efficacy in reducing central neuropathic pain following spinal cord injury compared to placebo in a global Phase III study. The company provided top-line data only.